The Lynx Group

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.
Results from TRANSCEND CLL 004 showed chimeric antigen receptor (CAR) T-cell treatment with lisocabtagene maraleucel in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had failed ibrutinib was manageable and produced durable undetectable minimal residual disease responses.
Read Article

Results from the 3-year update of the phase 2 AIM trial confirmed the effectiveness of ibrutinib + venetoclax therapy for patients with mantle-cell lymphoma, and indicated that treatment interruption was feasible for patients in minimal residual disease–negative complete remissions.
Read Article

A large observational study showed increased first-line bendamustine-rituximab use among older patients with splenic or nodal marginal zone lymphoma was not associated with significant event-free survival or overall survival benefit versus single-agent rituximab, but led to increased toxicities and costs.
Read Article

Updated results from a phase 1/2 trial indicate that acalabrutinib monotherapy was associated with a favorable safety profile and showed antileukemic activity in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, irrespective of high-risk genomic features.
Read Article

Pharmacy’s Emerging Influence and the Roles Pharmacists Play
Leaders in oncology pharmacy tackle some of the biggest issues in the field today in a pre-summit professional development session.
Read Article

Cancer Centers and the Integrated Health Delivery Systems and the Cancer Care Value Perspectives

Insurance Payers and the Cancer Care Value Perspectives

Keynotes Highlight a Successful Summit—Stellar Duo Delivers Outstanding Talks
A pair of distinguished keynote speakers gave attendees a rare behind-the-scenes look at healthcare policy decisions at the highest levels.
Read Article

Working with Integrated Health Delivery Systems in Cancer Care Ecosystem
The Summit kicked off with opening remarks and the first of the event’s in-depth pre-summit professional development sessions—designed to take a deep dive into select topics.
Read Article

In a prospective trial, the VEGFR-2 small-molecule inhibitor apatinib has shown promising efficacy and safety signals.
Read Article

Page 1 of 16

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: